Hepa Meraz Infusion
L-Ornithine + L-Aspartate
Win-Medicare Pvt. Ltd.
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price |
Available as:
Indications
Hepa Meraz Infusion is used for:
Treatment of hyperammonemia due to acute or chronic liver disease, e.g., liver cirrhosis, fatty liver and hepatitis.
Treatment of precoma of hepatic encephalopathy.
Adult Dose
Oral
1-2 tab three times a day
Child Dose
Renal Dose
Administration
Contra Indications
Hypersensitivity to L-ornithine-L-aspartate.
Severely impaired renal function (renal insufficiency).
Precautions
There are no clinical data available on the use of L-ornithine-L-aspartate in pregnancy. It is not known whether L-ornithine-L-aspartate secreted into breast milk. Therefore, administration of L-ornithine-L-aspartate should be avoided during lactation. Depending on the underlying disease, the ability to drive and operate machines may also be impaired on treatment with L-ornithine-L-aspartate.
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of L-Ornithine + L-Aspartate :
Nausea, vomiting, sensation of heat and palpitation. Generally, these symptoms are transient and do not necessitate discontinuation of treatment with L-ornithine-L-aspartate. The symptoms disappear on reduction of the dose or infusion rate.
Mechanism of Action
Note
Hepa Meraz Infusion manufactured by Win-Medicare Pvt. Ltd.. Its generic name is L-Ornithine + L-Aspartate. Hepa Meraz is availble in Nepal.
Farmaco Nepal drug index information on Hepa Meraz Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.